Abstract: PO0708
Severe AKI in SARS-COVID-19 Patients from a Tertiary Hospital in Rhode Island
Session Information
- COVID-19: AKI and Outcomes
October 22, 2020 | Location: On-Demand
Abstract Time: 10:00 AM - 12:00 PM
Category: Coronavirus (COVID-19)
- 000 Coronavirus (COVID-19)
Authors
- Kota, Harshitha, Brown University, Providence, Rhode Island, United States
- Mitchell, Kevin, Brown University, Providence, Rhode Island, United States
- Tang, Jie, Brown University, Providence, Rhode Island, United States
Background
The clinical features & outcomes of COVID-19 patients who developed severe AKI are still being elucidated.
Methods
42 patients with COVID-19 infection who developed KDOGI stage 3 AKI were identified from March 1 to May 15, 2020, at Rhode Island Hospital, a large tertiary teaching hospital. Their clinical presentations and outcomes are presented. The data in table 1 were presented as mean (± SD), median (IQR), or # (%).
Results
The baseline characteristics are outlined in table 1. Among them, 88% were admitted to ICU, 83% were intubated and needed pressor support. 71% received renal replacement therapy (RRT)(56% on CVVHDF). The mean duration of RRT and ICU stay were 6 and 14 days, respectively. 33 participants received treatment for COVID-19, among them 14 (33%) received Remdesivir(RDV), 6 (14%) received convalescent plasma(CP), 4 (10%) received hydroxychloroquine(HCQ), and 25 (60%) also received azithromycin. The mortality rates were 15% in the RDV group, 67% in the CP group, and 75% in the HCQ group. The mortality was 67% in those without any treatment. At the 60-day follow-up, 11 (26%) were discharged alive, 21 (50%) died. Those who died were older (mean age 71 vs. 61), having higher Charlson Comorbidity Index (4.7 vs 3.0), more likely to have diabetes (71% vs. 61%) and coronary artery disease (38% vs. 24%).
Conclusion
The mortality rate of SARS-COVID patients who developed severe AKI is high in our cohort. Future larger scale studies are needed to elucidate the causes of this high mortality.
Table 1 Baseline and Presenting characteristics of the cohort
| Total Participants, n=42 | |
| Age | 64(56-72) |
| Sex, Male | 33(79%) |
| Hispanic | 19(45%) |
| White | 12(29%) |
| HTN | 35(83%) |
| DM | 28(67%) |
| HLD | 26(62%) |
| CAD | 13(31%) |
| CHF | 6(14%) |
| COPD/Asthma | 4(10%) |
| Atrial fibrillation | 3(7%) |
| Baseline CKD | 20(48%) |
| Charlson Comorbidity Index | 3.7(±1.9) |
| Smoking,Never | 18(43%) |
| BMI | 31.4(±6.7) |
| Symptom, duration <1 week | 30(71%) |
Funding
- Clinical Revenue Support